# NePtune (NCT05498272)

> Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations

No report yet. It can be ordered.

- Drugs tested: olaparib plus goserelin; olaparib plus triptorelin; olaparib plus leuprolide
- Indication: unfavorable intermediate-risk/high-risk prostate cancer with HRR gene alterations

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05498272
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Rana McKay, MD
- Conditions: Prostate Cancer; BRCA1 Mutation; BRCA2 Mutation; Prostatic Adenocarcinoma; High-Risk Cancer
- Interventions: Olaparib; LHRH agonist
- Enrollment: 32
- Primary outcome: Pathological Complete Response (pCR) rate
- Primary outcome: Minimal Residual Disease (MRD) rate

## Indexed commentary on NePtune so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=neptune-nct05498272